Robert Constant
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1124039458
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,519 of the $6,628 with a category attached, or 68.2%. It is spread thinly across 36 manufacturers, the largest accounting for just 23.9%. Reporting peaked in 2020 at $2,593 and has fallen 99.3% since, to $17 in 2023.
Across 298 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Tosoh Bioscience, Inc.$1K
- Novo Nordisk$675
- Amgen$437
- AbbVie$236
- Radius Health, Inc.$215
- plus $2K from 30 others
What the payments were for
- Travel & lodging$98215%
- Food & beverage$4,51968%
- Education$60%
- Gifts$1,12117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 66 | $1,585 |
| Tosoh Bioscience, Inc. | 1 | $1,121 |
| Novo Nordisk | 44 | $675 |
| Amgen(2 entities) | 23 | $437 |
| AbbVie | 15 | $236 |
| Radius Health, Inc. | 11 | $215 |
| Boehringer Ingelheim | 12 | $195 |
| Abbott | 12 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $182 |
| Sanofi-aventis U.S. LLC | 10 | $172 |
| IBSA Pharma Inc. | 10 | $168 |
| Xeris Pharmaceuticals, Inc. | 7 | $139 |
| Johnson & Johnson | 9 | $122 |
| Tandem Diabetes Care, Inc. | 4 | $121 |
| Lilly USA, LLC | 6 | $118 |
| AstraZeneca(2 entities) | 6 | $114 |
| Dexcom, Inc. | 4 | $89 |
| Insulet Corporation | 5 | $80 |
| Amneal Pharmaceuticals LLC | 5 | $73 |
| Shire North American Group Inc | 1 | $71 |
| Antares Pharma, Inc. | 4 | $69 |
| Lifescan, Inc. | 4 | $56 |
| Merck | 4 | $51 |
| Corcept Therapeutics | 3 | $45 |
| Zealand Pharma US, Inc. | 3 | $45 |
| Mannkind Corporation | 3 | $43 |
| Pfizer | 2 | $35 |
| GRT US Holding, Inc. | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $33 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Roche Diabetes Care, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Vistapharm, Inc. | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- G8 Column$1,121
- Minimed 670G System$866
How this compares
$6,628 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Other endocrinology, diabetes & metabolism in Orlando
- Damon TantonOrlando$1.2M
- Richard PratleyOrlando$735K
- Hanford YauOrlando$489K
- Steven SmithOrlando$390K
- Tina ThethiOrlando$244K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.